Milestone Pharmaceuticals Inc. disclosed a material event
SEC 8-KRead source ↗
Milestone Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$0.5
Forward price-to-sales vs peers
Base case. Range ~$0.5–$1.9. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Milestone Pharmaceuticals Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 5 selling0 purchases and 13 sales by directors and officers, last 12 monthsInsider trades
- Funds29 adding, 35 cuttingOf 13 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 9% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Milestone Pharmaceuticals Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 75% and a beta of 2.5 against the S&P 500.
- Heavily shorted. 15.9% of the shares available to trade are sold short (16.9 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.21 against an average estimate of -$0.19: missed by 9.1%
- Share reaction
- -15.7% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
- Next report
- November 12, 2026; average EPS estimate -$0.21
Price chart
- 1 day-1.2%
- 1 week+12.0%
- 1 month-11.0%
- This year-64.3%
- 1 year-62.4%
- 5 years-87.2%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 12, 2026
- Next results (est.)
- November 11, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Results
Milestone Pharmaceuticals Inc. reported results
SEC 8-KRead source ↗
Valuation models
We value Milestone Pharmaceuticals Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.53 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: no revenue, margin or share count to start from |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.5 ~$0.5–$1.9 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$0.5 ~$0.5–$1.9 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Milestone Pharmaceuticals Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, before the open. Analysts expect revenue of $1m and EPS of −$0.21 (range −$0.23 to −$0.20) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.84 | −12% | $3m | +125% |
| Next | −$0.78 | +7% | $20m | +463% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +1.4% on 90 days ago. In the last 30 days, 1 analyst raised Milestone Pharmaceuticals Inc.'s forecast and 3 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.83 | −$0.91 |
| 60 days ago | −$0.84 | −$0.77 |
| 30 days ago | −$0.84 | −$0.77 |
| 7 days ago | −$0.84 | −$0.77 |
| Now | −$0.84 | −$0.78 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.19 | −$0.21 | −9.1% |
| Mar 2026 | $0.19 | −$0.20 | −206.7% |
| Dec 2025 | −$0.18 | −$0.15 | +15.1% |
| Sept 2025 | −$0.17 | −$0.12 | +28.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 15.9% of tradable shares
- Days to cover
- 16.85 at average volume
- Short interest, 1 month
- +7% to October 15, 2026
- Held by institutions
- 52% of shares
- Held by insiders
- 0.7% of shares
- Employees
- 38 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| MIST | −2% | −40% | −58% | +41% | −14% | −64% |
| Industry peers (median) | −36% | −57% | −17% | −29% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| MIST | 50% | 58% | 42% | 50% | 50% | 18% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| MIST | −41% | −63% | −62% | −41% | −73% | −71% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since May 9, 2019: 98% from June 28, 2019 to October 26, 2026. Getting back needed a 4116% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.64 – $2.95
- From 52-week high
- −75.6%
- vs 50-day average
- −18.6%
- vs 200-day average
- −47.3%
- Volatility (1 year)
- 75%
- Beta vs S&P 500
- 2.53
Share price after results
- Next day
- 5 up, 7 down typical move ±11.3%
- After a week
- 7 up, 5 down typical move ±14.7%
- After a month
- 6 up, 6 down typical move ±22.4%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 12, 2026 | −15.7% | +0.9% | −15.0% | −22.8% |
| May 13, 2026 | −14.2% | +1.4% | −21.1% | −33.2% |
| March 20, 2026 | −25.9% | −0.4% | −38.8% | +12.9% |
| November 12, 2025 | −0.5% | −1.6% | +22.0% | +26.2% |
| August 12, 2025 | +12.3% | +1.4% | +7.7% | +23.2% |
| May 14, 2025 | −3.4% | +0.6% | +16.0% | +38.7% |
| March 13, 2025 | +12.4% | +0.7% | +1.0% | −60.1% |
| November 12, 2024 | −5.2% | −0.3% | −10.3% | −4.1% |
| August 8, 2024 | +6.0% | +2.8% | +1.5% | +8.3% |
| May 13, 2024 | +1.2% | +0.5% | +2.6% | −16.5% |
| March 21, 2024 | +16.0% | +0.1% | +19.3% | +8.7% |
| November 13, 2023 | −23.0% | +1.8% | −21.6% | −13.7% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $68.1M
- Institutions reporting
- 78
- Shares held vs prior quarter
- ▲ 28.6%
- Positions opened / closed
- 6 / 12
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Pavaki Capital Management LLC | $12.2M | 9.1M | 17.8% | ▲ 0.1% |
| RTW Investments, LP | $10.5M | 7.8M | 15.4% | ▲ 23.7% |
| Propel Bio Management, LLC | $10M | 7.4M | 14.6% | ▲ 80.4% |
| Point72 Asset Management, L.P. | $7.3M | 5.4M | 10.6% | ▲ 398.4% |
| Simplify Asset Management Inc. | $4.5M | 3.3M | 6.6% | ▲ 122.3% |
| Millennium Management LLC | $4.2M | 3.1M | 6.2% | ▲ 103.5% |
| Kalehua Capital Management LLC | $3.4M | 2.5M | 5.0% | New |
| Two Sigma Investments, LP | $2.7M | 2.0M | 4.0% | ▼ 12.0% |
| Marshall Wace, LLP | $2.4M | 1.8M | 3.5% | ▼ 7.6% |
| Lion Point Capital, LP | $1.1M | 820K | 1.6% | 0.0% |
| Toronto Dominion Bank | $1M | 750K | 1.5% | 0.0% |
| Boxer Capital Management, LLC | $893,332 | 667K | 1.3% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Milestone Pharmaceuticals Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.2M 13 trades by 5 insiders · 15% under pre-set plans
Net ▼ $1.2M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Oliveto Joseph President and CEO | April 16, 2026 | Sell pre-set plan | 36,500 | $2.26 | $82,490 |
| Oliveto Joseph President and CEO | January 26, 2026 | Sell | 34,523 | $1.93 | $66,629 |
| Hasija Amit CFO & EVP of Corp. Development | January 26, 2026 | Sell | 12,245 | $1.93 | $23,633 |
| Muller Lorenz Chief Commercial Officer | January 26, 2026 | Sell | 11,180 | $1.93 | $21,577 |
| Nelson Jeffrey Edward Chief Operating Officer | January 26, 2026 | Sell | 12,245 | $1.93 | $23,633 |
| Bharucha David Chief Medical Officer | January 26, 2026 | Sell | 12,245 | $1.93 | $23,633 |
| Oliveto Joseph President and CEO | January 8, 2026 | Sell pre-set plan | 43,000 | $2.25 | $96,750 |
| Oliveto Joseph President and CEO | January 7, 2026 | Sell pre-set plan | 500 | $2.25 | $1,125 |
| Oliveto Joseph President and CEO | December 15, 2025 | Sell | 133,054 | $2.32 | $308,685 |
| Hasija Amit CFO & EVP of Corp. Development | December 15, 2025 | Sell | 58,007 | $2.32 | $134,576 |
| Muller Lorenz Chief Commercial Officer | December 15, 2025 | Sell | 53,566 | $2.32 | $124,273 |
| Nelson Jeffrey Edward Chief Operating Officer | December 15, 2025 | Sell | 58,007 | $2.32 | $134,576 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced
- August 12, 2026
- May 13, 2026
- March 20, 2026
- November 12, 2025
- August 12, 2025
- May 14, 2025
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- S-3 S-3
- 8-K Current report
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Milestone Pharmaceuticals Inc. in brief
- What does Milestone Pharmaceuticals Inc. do?
- Milestone Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Milestone Pharmaceuticals Inc.'s stock ticker?
- Milestone Pharmaceuticals Inc. trades under the ticker MIST on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Milestone Pharmaceuticals Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Pavaki Capital Management LLC, RTW Investments, LP and Propel Bio Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Milestone Pharmaceuticals Inc. stock?
- Over the last 12 months, Milestone Pharmaceuticals Inc.'s directors and officers reported 0 open-market purchases and 13 sales on Form 4. The insider trading page charts every trade.
- When is Milestone Pharmaceuticals Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Milestone Pharmaceuticals Inc. announces its own schedule.
Follow research on Milestone Pharmaceuticals Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.